HIGHLIGHT
Saxenda

Saxenda

liraglutide

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Liraglutide
Indications/Uses
As adjunct to a reduced-calorie diet & increased physical activity for wt management in adults w/ an initial BMI of ≥30 kg/m2 (obese), or ≥27 kg/m2 to <30 kg/m2 (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (pre-diabetes or type 2 DM), HTN, dyslipidaemia or obstructive sleep apnoea.
Dosage/Direction for Use
SC Inj in the abdomen, thigh or upper arm. Initially 0.6 mg once daily. Dose should be increased to 3 mg once daily in increments of 0.6 mg w/ at least 1 wk intervals. Max daily dose: 3 mg.
Contraindications
Hypersensitivity. Patients w/ personal or family history of medullary thyroid carcinoma or in patients w/ multiple endocrine neoplasia syndrome type 2.
Special Precautions
Must not be administered IV or IM. Do not use as substitute for insulin in patients w/ DM. Patients w/ CHF (NYHA class IV); concomitant use w/ other products for wt management; w/ obesity secondary to endocrinological or eating disorders or to treatment w/ medicinal products that may cause wt gain; severe renal & hepatic impairment; inflammatory bowel disease & diabetic gastroparesis. Caution use in patients w/ mild or moderate hepatic impairment & thyroid disease. Discontinue use if pancreatitis is suspected; if patient experience a clinically relevant sustained increase in resting heart rate. Cholelithiasis & cholecystitis. Monitor heart rate at regular intervals. Potential risk of dehydration in relation to GI side effects; avoid fluid depletion. Concomitant use w/ sulfonylurea. Pregnancy & lactation. Childn & adolescents <18 yr. Elderly ≥75 yr.
Adverse Reactions
Nausea, vomiting, diarrhoea, constipation. Hypoglycaemia; insomnia; dizziness, dysgeusia; dry mouth, dyspepsia, gastritis, GERD, upper abdominal pain, flatulence, eructation, abdominal distension; cholelithiasis; inj site reactions, asthenia, fatigue; increased lipase & amylase.
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Saxenda soln for inj 18 mg/3 mL
Packing/Price
3's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in